Evofem Biosciences annual operating margin
2020
2021
2022
2023
2024
2025
Evofem Biosciences Operating Margin Growth & History (EVFM)
Evofem Biosciences's operating margin was 16.71% for fiscal 2025.
View full Evofem Biosciences company overviewEvofem Biosciences annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 16.71% | +56.35 pp |
| 2024 | 2024-12-31 | −39.64% | +58.32 pp |
| 2023 | 2023-12-31 | −97.96% | +401.67 pp |
| 2022 | 2022-12-31 | −499.64% | +1523.66 pp |
| 2021 | 2021-12-31 | −2,023.30% | +21210.78 pp |
| 2020 | 2020-12-31 | −23,234.08% | — |
Evofem Biosciences quarterly operating margin
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −94.53% | −68.60 pp |
| Q1 2026 | 2026-03-31 | −508.23% | −546.93 pp |
| Q4 2025 | 2025-12-31 | 34.99% | +49.10 pp |
| Q3 2025 | 2025-09-30 | 19.20% | +73.47 pp |
| Q2 2025 | 2025-06-30 | −25.93% | +7.46 pp |
| Q1 2025 | 2025-03-31 | 38.70% | +117.63 pp |
| Q4 2024 | 2024-12-31 | −14.12% | +55.73 pp |
| Q3 2024 | 2024-09-30 | −54.27% | +15.21 pp |
| Q2 2024 | 2024-06-30 | −33.39% | +265.06 pp |
| Q1 2024 | 2024-03-31 | −78.93% | −17.32 pp |
| Q4 2023 | 2023-12-31 | −69.85% | +6588.71 pp |
| Q3 2023 | 2023-09-30 | −69.48% | +224.41 pp |
| Q2 2023 | 2023-06-30 | −298.45% | +106.24 pp |
| Q1 2023 | 2023-03-31 | −61.61% | +618.91 pp |
| Q4 2022 | 2022-12-31 | −6,658.56% | −5610.44 pp |
| Q3 2022 | 2022-09-30 | −293.89% | +2239.34 pp |
| Q2 2022 | 2022-06-30 | −404.69% | +1810.82 pp |
| Q1 2022 | 2022-03-31 | −680.52% | +3380.29 pp |
| Q4 2021 | 2021-12-31 | −1,048.12% | +20292.35 pp |
| Q3 2021 | 2021-09-30 | −2,533.24% | +6875.40 pp |
| Q2 2021 | 2021-06-30 | −2,215.51% | — |
| Q1 2021 | 2021-03-31 | −4,060.81% | — |
| Q4 2020 | 2020-12-31 | −21,340.48% | — |
| Q3 2020 | 2020-09-30 | −9,408.63% | — |
Evofem Biosciences operating margin trends
Over the last five reported fiscal years, Evofem Biosciences's operating margin increased from −23,234.08% to 16.71%, a change of +23250.79 percentage points. The latest reported quarter, Q2 2026, shows −94.53%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Evofem Biosciences filings at SEC.gov ↗